- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01400893
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
April 2, 2021 updated by: SeaStar Medical
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).
Study Overview
Detailed Description
Acute kidney injury is a condition where the kidneys are not capable of producing adequate urine.
Therefore, another way to remove waste from the body is needed to hopefully allow time for the kidneys to heal.
One method of removing waste from the body is called Continuous Renal Replacement Therapy (CRRT) or variations of that therapy.
This study will evaluate the safety of the device while it is connected to the CRRT tubing for up to 7 days.
Patients will be followed up until day 60 following the treatment.
Study Type
Interventional
Enrollment (Actual)
134
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama Birmingham
-
-
California
-
Los Angeles, California, United States, 90025
- UCLA
-
San Diego, California, United States, 92103
- University of California, San Diego
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
Jacksonville, Florida, United States, 32209
- University of Florida
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Beth Isreal Deaconess Medical Center
-
Springfield, Massachusetts, United States, 01199
- Baystate Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
New York
-
Albany, New York, United States, 12208
- Albany Medical College
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine
-
-
North Dakota
-
Fargo, North Dakota, United States, 58122
- Sanford Health
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37403
- Memorial Hospital
-
Chattanooga, Tennessee, United States, 37404
- Erlanger Hospital
-
-
Texas
-
Dallas, Texas, United States, 75216
- Dallas VA Medical Center
-
Houston, Texas, United States, 77030
- University of Texas
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Inova Health Care Services
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- A patient, or legal representative, has signed a written informed consent form.
- Must be receiving medical care in an intensive care unit (e.g., ICU, MICU, SICU, CTICU, Trauma).
- Age 18 to 80 years.
- Females of child bearing potential who are not pregnant (confirmed by a negative serum pregnancy test) and not lactating if recently post-partum.
- Must be receiving and tolerating CRRT therapy for a minimum of 4 hours, but not longer than 24.
- Expected to remain in the ICU for at least 96 hours after evaluation for enrollment.
- A clinical diagnosis of ATN due to hemodynamic or toxic etiologies. ATN is defined as Acute Kidney Injury occurring in a setting of acute ischemic or nephrotoxic injury with oliguria (average <20 mL/hr) for >6-12 hours or: an increase in serum creatinine ≥2 mg/dL (≥1.5 mg/dL in females) over a period of ≤4 days. (Note: Prerenal, hepatorenal, vascular, interstitial, glomerular, and obstructive etiologies are excluded on clinical or other diagnostic grounds.)
- Presence of at least one non-renal organ failure or present sepsis as defined in Appendix C.
- All patients must be able to tolerate regional citrate anticoagulation.
Exclusion Criteria:
- Irreversible brain damage based on available historical and clinical information.
- Presence of any organ transplant at any time.
- Acute or chronic use of circulatory support device such as LVADs, RVADs, BIVADs, ECMO.
- Presence of preexisting advanced chronic renal failure (i.e., ESRD) requiring chronic renal replacement therapy prior to this episode of acute kidney injury.
- AKI occurring in the setting of burns, obstructive uropathy, allergic interstitial nephritis, acute or rapidly progressive glomerulonephritis, vasculitis, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP), malignant hypertension, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, hepatorenal syndrome, cyclosporine or tacrolimus nephrotoxicity.
- Metastatic malignancy which is actively being treated or may be treated by chemotherapy or radiation during the subsequent three month period after study therapy.
- Chronic immunosuppression (e.g., HIV/AIDS, chronic glucocorticoid therapy >20 mg/day prednisone equivalent on a chronic basis). The acute use of glucocorticoids is permissible.
- Severe liver failure as documented by a Child-Pugh Liver Failure Score >12 (see Appendix F).
- Currently in Do Not Resuscitate (DNR) status or DNR status anticipated within the next 7 days.
- Currently in Comfort measures Only or Comfort Measures Only status anticipated within next 7 days.
- Patient is moribund or chronically debilitated for whom full supportive care is not indicated.
- Patient not expected to survive 28 days because of an irreversible medical condition. (This is not restrictive to AKI, and may include situations such as the presence of irreversible brain damage, untreatable malignancy, inoperable life threatening condition, or any condition to which therapy is regarded as futile by the PI.)
- Any medical condition that the Investigator thinks may interfere with the study objectives.
- Physician refusal.
- Patient is a prisoner.
- Dry weight of >150 kg.
- More than one hemodialysis treatment during this hospital admission or prior to transfer from an outside hospital.
- Platelet count <30,000/mm3 at time of screening.
- Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical trials where only measurements and/or samples are taken (NO TEST DEVICE OR TEST DRUG USED) are allowed to participate.
- Use of any other Investigational drug or device within the previous 30 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CRRT + SCD
Patients with a diagnosis of AKI requires CRRT will be randomized
|
The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge.
The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device.
Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD.
Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit.
Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
|
No Intervention: CRRT alone
Patients with a diagnosis of AKI requires CRRT will be randomized
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Primary Clinical Efficacy Endpoint in This Trial is All Cause Mortality Through 60 Days Post-randomization.
Time Frame: Day 60 following treatment initiation
|
All cause mortality through day 60 post-randomization. The outcome data reported here describe the mortality at Day 60 (primary endpoint) of the treated subjects which received the recommended ionized calcium (riCa) for ≥ 90% of treatment time. |
Day 60 following treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renal Replacement Therapy Dependency at Day 60.
Time Frame: Day 60 following treatment initiation
|
RRT dependency at day 60 is defined as patient not receiving any form of intermittent or continuous renal replacement therapy at 60 days post enrollment in the study with no plans for additional intermittent or continuous renal replacement therapy.
|
Day 60 following treatment initiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2011
Primary Completion (Actual)
September 1, 2013
Study Completion (Actual)
September 1, 2013
Study Registration Dates
First Submitted
July 21, 2011
First Submitted That Met QC Criteria
July 21, 2011
First Posted (Estimate)
July 25, 2011
Study Record Updates
Last Update Posted (Actual)
April 27, 2021
Last Update Submitted That Met QC Criteria
April 2, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCD-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
University Hospital, GhentWithdrawn
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
-
University Hospital MuensterBaxter Healthcare CorporationCompletedAcute Kidney Injury (AKI)Spain, France, United States, Turkey, Germany, Egypt, Italy, Libyan Arab Jamahiriya, Malta, North Macedonia, Palestinian Territory, occupied, Russian Federation, Saudi Arabia, Slovenia
-
Chinese PLA General HospitalBeijing Tsinghua Changgeng HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Chinese PLA General HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Astellas Pharma IncCompleted
-
South Egypt Cancer InstituteCompletedAcute Kidney Injury (AKI)Egypt
-
Xuzhou Medical UniversityUnknownPostoperative Acute Kidney Injury
Clinical Trials on SCD
-
Seattle Children's HospitalCompleted
-
Sun Pharmaceutical Industries LimitedRecruitingDermatitis, AtopicUnited States, El Salvador
-
Sun Pharmaceutical Industries LimitedRecruitingModerate to Severe Plaque PsoriasisUnited States, El Salvador
-
CytoPherx, IncChildren's Hospital Medical Center, Cincinnati; Innovative BioTherapies (IBT)Completed
-
SeaStar MedicalCompletedAKI | COVID | ARDSUnited States
-
TriHealth Inc.Active, not recruitingHypotension | Labor ComplicationUnited States
-
University Hospitals Cleveland Medical CenterCase Western Reserve UniversityRecruiting
-
Invenux, LLCState University of New York - Downstate Medical CenterActive, not recruitingSickle Cell Disease | Sickle-Beta Zero ThalassemiaUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedSickle Cell DiseaseUnited States
-
Emory UniversityNational Center for Complementary and Integrative Health (NCCIH)Recruiting